Eight-fold increased COVID-19 mortality in autosomal dominant tubulointerstitial kidney disease due to MUC1 mutations: an observational study

• Published in: BMC nephrology 2024-12, Vol.25 (1), p.449-10
• Main Authors: Kidd, Kendrah O, Williams, Adrienne H, Taylor, Abbigail, Martin, Lauren, Robins, Victoria, Sayer, John A, Olinger, Eric, Mabillard, Holly R, Papagregoriou, Gregory, Deltas, Constantinos, Stavrou, Christoforos, Conlon, Peter J, Hogan, Richard Edmund, Elhassan, Elhussein A E, Springer, Drahomíra, Zima, Tomáš, Izzi, Claudia, Vrbacká, Alena, Piherová, Lenka, Pohludka, Michal, Radina, Martin, Vylet'al, Petr, Hodanova, Katerina, Zivna, Martina, Kmoch, Stanislav, Bleyer, Sr, Anthony J
• Format: Article
• Language: English
• Subjects: Adult; Aged; Autosomal Dominant Tubulointerstitial kidney disease; CA15-3; Complications and side effects; COVID-19; COVID-19 - genetics; COVID-19 - mortality; Female; Gene mutations; Genetic aspects; Genetic disorders; Health aspects; Humans; Kidney diseases; Male; Middle Aged; MUC1; Mucin-1; Mucin-1 - blood; Mutation; Nephritis, Interstitial - genetics; Patient outcomes; Registries; SARS-CoV-2 - genetics; Statistics; UMOD; Uromodulin
• ISSN: 1471-2369; 1471-2369
• DOI: 10.1186/s12882-024-03896-1

MUC1 and UMOD pathogenic variants cause autosomal dominant tubulointerstitial kidney disease (ADTKD). MUC1 is expressed in kidney, nasal mucosa and respiratory tract, while UMOD is expressed only in kidney. Due to haplo-insufficiency ADTKD-MUC1 patients produce approximately 50% of normal mucin-1. To determine whether decreased mucin-1 production was associated with an increased COVID-19 risk, we sent a survey to members of an ADTKD registry in September 2021, after the initial, severe wave of COVID-19. We linked results to previously obtained ADTKD genotype and plasma CA15-3 (mucin-1) levels and created a longitudinal registry of COVID-19 related deaths. Surveys were emailed to 637 individuals, with responses from 89 ADTKD-MUC1 and 132 ADTKD-UMOD individuals. 19/83 (23%) ADTKD-MUC1 survey respondents reported a prior COVID-19 infection vs. 14/125 (11%) ADTKD-UMOD respondents (odds ratio (OR) 2.35 (95%CI 1.60-3.11, P = 0.0260). Including additional familial cases reported from survey respondents, 10/41 (24%) ADTKD-MUC1 individuals died of COVID-19 vs. 1/30 (3%) with ADTKD-UMOD, with OR 9.21 (95%CI 1.22-69.32), P = 0.03. The mean plasma mucin-1 level prior to infection in 14 infected and 27 uninfected ADTKD-MUC1 individuals was 7.06 ± 4.12 vs. 10.21 ± 4.02 U/mL (P = 0.035). Over three years duration, our longitudinal registry identified 19 COVID-19 deaths in 360 ADTKD-MUC1 individuals (5%) vs. 3 deaths in 478 ADTKD-UMOD individuals (0.6%) (P = 0.0007). Multivariate logistic regression revealed the following odds ratios (95% confidence interval) for COVID-19 deaths: ADTKD-MUC1 8.4 (2.9-29.5), kidney transplant 5.5 (1.6-9.1), body mass index (kg/m ) 1.1 (1.0-1.2), age (y) 1.04 (1.0-1.1). Individuals with ADTKD-MUC1 are at an eight-fold increased risk of COVID-19 mortality vs. ADTKD-UMOD individuals. Haplo-insufficient production of mucin-1 may be responsible.